Reviva Pharmaceuticals Holdings Inc.

RVPH | $4.09 11.14% 10.02% 1.3M

(0.0% 1d) (-29.1% 1m) (1.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-36.78% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 92,639,588
https://revivapharma.com
Sec Filling | Patents | 5 employees

Reviva Pharmaceuticals, Inc. is a clinical stage pharmaceutical company developing therapies that address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases. Reviva's primary focus is developing its lead product candidate, RP5063 (brilaroxazine), for the treatment of schizophrenia, bipolar disorder, and major depressive disorder. Reviva also intends to develop RP5063 for treating PAH and IPF. RP5063 is a serotonin, dopamine, and nicotinic receptor active compound, which has successfully completed a global Phase 2 clinical trial and has shown clinical efficacy and safety for schizophrenia and schizoaffective disorder.

urea treatment schizophrenia nervous system cardiovascular metabolic

add to watch list email alert is off

Press-releases

Reviva Pharmaceuticals to Participate in The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
Published: 2023-11-30 (Crawled : 22:00) - revivapharma.com
RVPH | $4.09 11.14% 10.02% 1.3M

| Email alert Add to watchlist
conference pharmaceuticals

Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Published: 2023-11-20 (Crawled : 21:00) - globenewswire.com
RVPH | $4.09 11.14% 10.02% 1.3M

| -9.03% | O: -2.85% H: 13.69% C: 9.05%
nasdaq direct offering

Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Published: 2023-11-16 (Crawled : 13:00) - globenewswire.com
RVPH | $4.09 11.14% 10.02% 1.3M

| -30.62% | O: -13.04% H: 0.21% C: -4.69%
nasdaq direct offering

Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Published: 2023-11-14 (Crawled : 21:00) - globenewswire.com
RVPH | $4.09 11.14% 10.02% 1.3M

| -35.79% | O: -7.46% H: 0.0% C: 0.0%
business financial results

Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
Published: 2023-10-30 (Crawled : 12:00) - biospace.com/
RVPH | $4.09 11.14% 10.02% 1.3M

| -1.03% | O: 29.46% H: 35.73% C: 9.58%
brilaroxazine positive global topline schizophrenia trial results

Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia
Published: 2023-09-25 (Crawled : 10:00) - revivapharma.com
RVPH | $4.09 11.14% 10.02% 1.3M

| -22.78% | O: -1.21% H: 2.1% C: -1.84%
brilaroxazine schizophrenia trial

Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Published: 2023-09-07 (Crawled : 10:00) - globenewswire.com
RVPH | $4.09 11.14% 10.02% 1.3M

| -4.25% | O: -1.25% H: 4.56% C: 3.04%
conference global

Reviva Pharmaceuticals Holdings, Inc. Reports Third Quarter 2022 Financial Results and Recent Business Highlights
Published: 2023-08-26 (Crawled : 00:20) - revivapharma.com
RVPH | $4.09 11.14% 10.02% 1.3M

| Email alert Add to watchlist
business pharmaceuticals financial results

Reviva Pharmaceuticals Announces Canadian Composition of Matter Patent for Triple Reuptake Inhibitor RP1208
Published: 2023-08-26 (Crawled : 00:20) - revivapharma.com
RVPH | $4.09 11.14% 10.02% 1.3M

| Email alert Add to watchlist
rp1208 patent pharmaceuticals

Reviva Pharmaceuticals Announces Positive Safety Data from Drug-Drug Interaction Clinical Study of Brilaroxazine
Published: 2023-08-26 (Crawled : 00:20) - revivapharma.com
RVPH | $4.09 11.14% 10.02% 1.3M

| Email alert Add to watchlist
brilaroxazine positive pharmaceuticals study

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001493152-23-042540	4	2023-11-22	2023-11-20	Buy	J	585366	585366
0001493152-23-042540	4	2023-11-22	2023-11-20	Buy	J	585366	585366